Page 2 - Wenbo Yao News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Gut microbiome linked to increased risk, severity of HIV, EBV diseases: Research
hindustantimes.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from hindustantimes.com Daily Mail and Mail on Sunday newspapers.
Gut microbiome can increase risk, severity of HIV, EBV disease
sciencedaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from sciencedaily.com Daily Mail and Mail on Sunday newspapers.
Gut Microbiome Boosts HIV, EBV Disease Risk, Severity
miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.
New study shows gut microbiome can increase risk, severity of HIV, EBV disease
medicalxpress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medicalxpress.com Daily Mail and Mail on Sunday newspapers.
by Mark Derewicz, staff reports February 9, 2021 .
CHAPEL HILL – An experimental drug created at a subsidiary of Emory University has shown potential to both prevent and treat COVID-19, according to researchers at UNC-Chapel Hill.
The drug, known as EIDD-2801, is being developed by Miami-based Ridgeback Biotherapeutics. Ridgeback is partnered with drug giant Merck in the development process. The drug was invented at Drug Innovations at Emory, a not-for-profit biotechnology company wholly owned by Emory University, according to Ridgeback.
Nature, scientists at the UNC School of Medicine and UNC Gillings School of Global Public Health tested how the orally administered experimental drug halts SARS-CoV-2 replication and prevents infection of human cells in a new in vivo [in a living organism] model containing human lung tissue.